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ABSTRACT
Background & aims: There are few validation studies of existing diagnostic criteria
for irritable bowel syndrome (IBS). We conducted a validation study of the Rome and
Manning criteria in secondary care.
Methods:We collected complete symptom, colonoscopy, and histology data from
1848 consecutive adult patients with gastrointestinal (GI) symptoms at 2 hospitals in
Hamilton, Ontario; the subjects then underwent colonoscopy. Assessors were blinded
to symptom status. Individuals with normal colonoscopy and histopathology
examination of biopsy specimens, and no evidence of celiac disease, were classified
as having no organic GI disease. The reference standard used to define the presence of
true IBS was lower abdominal pain or discomfort in association with a change in
bowel habit, and no organic GI disease. Sensitivity, specificity, and positive and
negative likelihood ratios (LRs), with 95% confidence intervals (CIs), were calculated
for each diagnostic criteria.
Results: In identifying patients with IBS, sensitivities of the criteria ranged from
61.9% (Manning) to 95.8% (Rome I), and specificities from 70.6% (Rome I) to 81.8%
(Manning). Positive LRs ranged from 3.19 (Rome II) to 3.39 (Manning), and negative
LRs from 0.06 (Rome I) to 0.47 (Manning). The level of agreement between
diagnostic criteria was greatest for Rome I and Rome II (N = 0.95), and lowest for
Manning and Rome III (N = 0.59).
Conclusions: Existing diagnostic criteria perform modestly in distinguishing IBS
from organic disease. There appears to be little difference in terms of accuracy. More
accurate ways of diagnosing IBS, avoiding the need for investigation, are required.
Keywords: Irritable bowel syndrome; Rome III criteria; accuracy; sensitivity;
specificity
Ford et al. 4 of 40
INTRODUCTION
Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder,
characterized by abdominal pain or discomfort, in association with altered stool form
or stool frequency.
1
The condition has a relapsing and remitting natural history,
2-5
with a prevalence of up to 20% in the general population,
6
and is commoner in
women.
7
Individuals with IBS are more likely to consume health care resources than
healthy individuals,
8
with up to 80% of sufferers consulting their primary care
physician as a result of symptoms.
9, 10
Diagnosing IBS can be challenging due to overlap between the symptoms that
sufferers report and those of organic GI conditions such as celiac disease,
11-13
small
intestinal bacterial overgrowth,
14
bile acid diarrhea,
15, 16
exocrine pancreatic
insufficiency,
17
or inflammatory bowel disease.
18
Partly as a result of this
uncertainty, symptom-based diagnostic criteria were developed for use by physicians
consulting with patients with suspected IBS as early as the 1970s, with Manning et al.
reporting six symptoms that were commoner among individuals found ultimately to
have IBS after investigation.
19
Community-based factor analysis studies demonstrate
that the symptoms thought to make up IBS cluster together, lending credence to the
biological plausibility of IBS as a distinct clinical entity.
20
These observations led to
the development of the Rome I criteria,
21
which have been revised on two subsequent
occasions to produce the Rome II and Rome III criteria.
1, 22
Guidelines for the management of IBS from national organizations encourage
physicians to make a positive diagnosis of IBS, using these symptom-based diagnostic
criteria, and to avoid extensive investigation.
23-25
Accurate diagnostic criteria for IBS
are of paramount importance, as they allow physicians to make the diagnosis with
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confidence, hence reducing the costs of managing the condition to the health service,
and reassure patients that their physician’s opinion is correct. However, a recent
systematic review and meta-analysis identified very few validation studies of existing
symptom-based diagnostic criteria.
26
Of the available criteria, only those of Manning
et al. had been subject to more than one validation.
19, 27-29
There was only one eligible
study examining the accuracy of the Rome I criteria,
30
despite the fact that they had
been published 18 years previously, and no studies of either the Rome II or Rome III
criteria.
At the time this meta-analysis was published the Rome III criteria had been
described only 2 years earlier. However, despite the fact that these criteria are the
accepted gold-standard for reaching a diagnosis of IBS, in the intervening 5 years no
validation study has been published. We have therefore conducted a study to validate
the Rome III criteria, and have compared their accuracy with other available
symptom-based diagnostic criteria for IBS.
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METHODS
Participants and Setting
The study was conducted among all individuals newly referred from primary
care to secondary care for consideration of investigation of GI symptoms. Unselected
FRQVHFXWLYHQHZSDWLHQWVDJHG\HDUVZHUHDSSURDFKHGLQWKH*,RXWSDWLHQWFOLQLFV
of McMaster University Medical Center or St. Joseph’s Healthcare, two hospitals in
Hamilton, Ontario serving a local population of 520,000. From January 2012 to
December 2012, 26% of the referrals were tertiary care in nature. There were no
exclusion criteria, other than an inability to understand written English. Potentially
eligible subjects were provided with a study information sheet at their initial clinic
visit, prior to consultation with a Gastroenterologist. Those who agreed to participate
were asked to provide written informed consent at that visit. The Hamilton Health
Sciences and McMaster University research ethics board approved the study in
January 2008, and recruitment continued until December 2012.
Data Collection and Synthesis
Demographic and Symptom Data
All demographic and symptom data were collected prospectively at the initial
clinic visit, and hence prior to referral for colonoscopy. Basic demographic data
included age, gender, ethnicity, marital status, educational level, lifestyle (tobacco and
alcohol use), height (in meters), and weight (in kilograms), which were used to
calculate body mass index (BMI). Symptom data were captured using the Rome III
diagnostic questionnaire for the adult functional GI disorders,
31
but we also collected
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data in order to examine the accuracy of the Manning, Rome I, and Rome II criteria in
diagnosing IBS. All questionnaire data were entered into a database by a trained
researcher who was not involved with the clinical care of the patient, thus ensuring
assessors were blinded to symptom status.
Definitions of IBS
The presence or absence of Rome III-defined IBS among individual patients
was assigned according to the scoring algorithm proposed for use with the Rome III
questionnaire, which is detailed in Supplementary Table 1. As the questionnaire
contained other symptom items, we were also able to classify the presence or absence
of IBS according to the following previously accepted gold-standard symptom-based
criteria, which preceded the Rome III criteria: the Manning criteria (using the
SUHVHQFHRIRIWKHVHWRGHILQH,%6LQRXUSULPDU\DQDO\VLVDVWKLVLVWKHPRVW
ZLGHO\DFFHSWHGWKUHVKROGEXWDOVRXVLQJRUFULWHULDLQDVHQVLWLYLW\DQDO\VLV19
the Rome I criteria,
21
and the Rome II criteria (see Supplementary Table 1).
22
We
conducted further sensitivity analyses where individuals reporting lower GI alarm
symptoms, including a positive family history of colorectal cancer, rectal bleeding,
weight loss, or anemia were excluded from the diagnosis of IBS using any of these
criteria.
In addition, in light of a recent report from a panel of experts in the field,
32
where it was felt that bloating was the most important feature of IBS, we performed
three sensitivity analyses using modified versions of the Rome III criteria. In these we
removed abdominal pain or discomfort from the definition and replaced it with
bloating at a frequency of once per week or more, we included the presence of both
abdominal pain or discomfort and bloating at a frequency of once per week or more,
Comment [AF1]: Should be four!
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we increased the frequency of abdominal pain or discomfort required to meet criteria
for IBS to daily, and we used abdominal pain or discomfort at a frequency of once per
week or more in combination with irregular bowel habit, defined using the presence
of hard stools and loose stools at a frequency of sometimes or more.
Colonoscopic and Histopathological Data
All included patients underwent complete colonoscopy to the cecum or
terminal ileum, using Pentax colonoscopes (Pentax Canada, Inc), following standard
bowel preparation, using either polyethylene glycol or sodium picosulphate
(depending on patient and physician preference). The responsible physician
performing colonoscopic examinations remained blinded to the symptom status of the
patient. Findings were recorded using the endoPRO reporting system (Pentax Canada,
Inc), and these reports were accessed by the study investigators in order to record the
ultimate colonoscopic diagnosis for each included patient. We classified the following
findings as being consistent with organic disease at colonoscopy: evidence of colitis
or terminal ileitis (inflammation or ulceration), colorectal carcinoma, stricture, or
evidence of radiation-induced colorectal disease. Diverticular disease, colorectal
adenoma, hemorrhoids or anal fissures were not considered to represent organic
disease.
Biopsy specimens were obtained at the discretion of the responsible physician
performing the colonoscopy. These specimens were interpreted by experienced GI
histopathologists, who remained blinded to the symptom status of the patient.
Histolopathological findings were recorded using the MEDITECH Healthcare
Reporting System (Medical Information Technology Inc, Westwood, MA), and this
was accessed by the study investigators in order to record the ultimate
Ford et al. 9 of 40
histopathological diagnosis. We classified the following findings as being consistent
with organic disease at histopathological examination of biopsy specimens: colonic or
rectal adenocarcinoma, ulcerative colitis, Crohn’s disease, inflammatory bowel
disease-unclassifiable, microscopic colitis, ischemic colitis, radiation enteritis,
ulceration seen macroscopically at colonoscopy with non-specific inflammation on
histological examination, or neuroendocrine tumour.
Definition of Organic Lower GI disease
Using these data we were able to classify patients according to the presence or
absence of organic lower GI disease. Individuals with no evidence of organic disease
at both colonoscopy and histopathological examination of biopsy specimens were
classified as exhibiting no organic lower GI disease, while those with evidence of
organic disease at either colonoscopy or histopathological examination of biopsy
specimens were classified as exhibiting organic lower GI disease.
Reference Standard
The reference standard used to define the presence of true IBS was the
presence of lower abdominal pain or discomfort at a frequency of at least once per
week in association with a change in bowel habit, in a patient who exhibited no
evidence of organic lower GI disease after colonoscopy and histological interpretation
of colonic biopsies (if obtained) that would explain these symptoms, and after
exclusion of celiac disease by distal duodenal biopsy obtained at upper GI endoscopy,
if celiac serology was positive.
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Statistical Analysis
In order to assess whether those who underwent colonoscopy were
representative of all patients seen in the two GI outpatient clinics demographic data
were compared between those undergoing colonoscopy who completed the symptom
questionnaire, and those who completed the symptom questionnaire but did not
XQGHUJRFRORQRVFRS\XVLQJDȤ2 test for categorical data, and an independent samples
t-test for continuous data, with a mean and standard deviation (SD). Due to multiple
comparisons a 2-tailed P value of <0.01 was considered statistically significant for
these analyses. We compared organic findings in those meeting the Rome III criteria
for IBS, with those who did not, using Fisher’s exact test, as numbers in each cell
were relatively small. We measured agreement between the various diagnostic criteria
for the presence of IBS using the modified Kappa statistic, where a value <0.2
indicates poor agreement and a value >0.8 indicates very good agreement beyond
chance. These statistical analyses were performed using SPSS for Windows version
19.0 (SPSS Inc, Chicago, IL, USA).
The primary aim of the study was to describe the performance of the Rome III
criteria for IBS in evaluating the presence of true IBS versus the reference standard.
However, we also wanted to compare the performance of the Rome III criteria for IBS
with previously available symptom-based diagnostic criteria including the Manning
criteria, the Rome I criteria, and the Rome II criteria. The sensitivity, specificity, and
positive and negative predictive values, and their 95% confidence intervals (CIs),
were calculated for each of these using a Microsoft Excel spreadsheet (XP
professional edition; Microsoft Corp, Redmond, WA, USA). The positive likelihood
ratio (LR) and negative LR, and their 95% CIs, were also calculated using the same
spreadsheet. The positive LR can be calculated from the formula: positive LR =
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sensitivity / (1-specificity), while the negative LR is derived from the formula:
negative LR = (1-sensitivity) / specificity. These calculations were checked using
Meta-DiSc® version 1.4 (Universidad Complutense, Madrid, Spain).
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RESULTS
There were a total of 4224 consecutive patients who gave informed consent
and were recruited in to the study between January 2008 and December 2012 (Figure
1). The mean age of recruited subjects was 47.6 years (range 16 to 93 years) and 2617
(62.0%) were female. In total, 1981 (46.9%) of these 4224 patients underwent
complete colonoscopic evaluation for their lower GI symptoms. The mean age among
those undergoing colonoscopy was 49.3 years (range 16 to 90), and 1251 (63.1%)
were female.
Degree of Overlap Between Different Diagnostic Criteria for IBS
There were 758 individuals who provided sufficient symptom data to examine
the degree of overlap between the four different diagnostic criteria for IBS. There was
agreement between all four criteria for the diagnosis of IBS in 360 (47.5%) subjects
(Figure 2). Another 179 (23.6%) met the Rome I, Rome II, and Rome III criteria, but
not the Manning criteria. There were 103 (13.6%) subjects who met the Manning
criteria, as well as the Rome I and Rome II criteria, but not the Rome III criteria.
Sixty-nine (9.1%) individuals met only the Rome I and Rome II criteria, and 11
(1.5%) only the Manning and Rome I criteria. Finally, 32 (4.2%) patients met only
one set of diagnostic criteria for IBS. The level of agreement between the four
symptom-based diagnostic criteria was greatest for the Rome I and Rome II criteria
(Kappa statistic = 0.95) (Table 1), and lowest for the Manning and Rome III criteria
(Kappa statistic = 0.59).
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Validation of the Rome III Criteria for IBS
There were 1848 individuals providing complete symptom, colonoscopy, and
histology data. Demographic data of all these patients, compared with the 2243
subjects who did not undergo colonoscopy, are provided in Table 2. Those
undergoing colonoscopy were slightly older, of higher BMI, and were more likely to
be White Caucasian, but there were no other significant differences in demographics,
including the number of patients who met the Rome III criteria for IBS, between
groups.
In total, 555 (30.0%) of the 1848 patients undergoing colonoscopy met the
Rome III criteria for IBS. The mean age of these 555 individuals was 42.5 years, and
413 (74.4%) were female. The prevalence of organic findings after investigation in
those who met the Rome III criteria for IBS, compared with those who did not, are
detailed in Table 3. None of these were significantly more common among those who
met criteria for IBS. Among the 365 patients with a diagnosis of IBS according to the
reference standard following colonoscopy and distal duodenal biopsy (where
appropriate), 251 met the Rome III criteria for IBS, giving a sensitivity of 68.8%
(Table 4). Among 1483 subjects who were not judged to have IBS according to the
reference standard, 1179 did not meet the Rome III criteria, giving a specificity of
79.5%. The positive LR of the Rome III criteria for the diagnosis of IBS was therefore
3.35 (95% CI 2.97 to 3.79), while the negative LR was 0.39 (95% CI 0.34 to 0.46).
Sensitivity analyses using the modifications to the Rome III criteria did not
lead to any improvement in their performance (Table 4). In particular, the replacement
of abdominal pain by bloating led to a decrease in the positive LR, and an increase in
the negative LR, while the inclusion of both abdominal pain and bloating in the
definition improved the positive LR, but the negative LR increased.
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Validation of the Rome II Criteria for IBS
When we attempted to validate the Rome II criteria, there were 1864
individuals providing complete symptom, colonoscopy, and histology data. Of these,
761 (40.8%) met the Rome II criteria for IBS (mean age 43.6 years, 551 (72.4%)
female). Among the 378 patients with a diagnosis of IBS according to the reference
standard, 341 met the Rome II criteria for IBS, giving a sensitivity of 90.2% (Table
4). Among 1486 subjects who were not judged to have IBS according to the reference
standard, 1066 did not meet the Rome II criteria, giving a specificity of 71.7%. The
positive LR of the Rome II criteria for the diagnosis of IBS was therefore 3.19 (95%
CI 2.92 to 3.48), while the negative LR was 0.14 (95% CI 0.10 to 0.19).
Validation of the Rome I Criteria for IBS
When we examined the validity of the Rome I criteria, there were 1866
individuals providing complete symptom, colonoscopy, and histology data. Of these,
799 (42.8%) met the Rome I criteria for IBS. The mean age of these 799 individuals
was 43.8 years, and 586 (73.3%) were female. There were 377 patients with a
diagnosis of IBS according to the reference standard following colonoscopy and distal
duodenal biopsy (where appropriate), and 361 of these met the Rome I criteria for
IBS, giving a sensitivity of 95.8% (Table 4). Among the 1489 individuals not judged
to have IBS according to the reference standard, 1051 did not meet the Rome I
criteria, giving a specificity of 70.6%. The positive LR of the Rome I criteria for the
diagnosis of IBS was 3.26 (95% CI 3.00 to 3.53), while the negative LR was 0.06
(95% CI 0.04 to 0.10).
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Validation of the Manning Criteria for IBS
Finally, when we attempted to validate the Manning criteria, there were 1854
individuals providing complete symptom, colonoscopy, and histology data. Of these,
498 (26.9%) met the Manning criteria for IBS (mean age 42.3 years, 366 (73.5%)
female). Among the 367 subjects with a diagnosis of IBS according to the reference
standard, 227 met the Manning criteria for IBS (sensitivity 61.9%) (Table 4). Among
1487 patients who did not have IBS according to the reference standard, 1216 did not
meet the Manning criteria (specificity 81.8%). The positive LR of the Manning
criteria for the diagnosis of IBS was 3.39 (95% CI 2.97 to 3.88), with a negative LR
RI&,WR:KHQRIWKH0DQQLQJFULWHULDZHUHXVHGWRGHILQH
presence of IBS in a sensitivity analysis, the positive LR remained very similar (3.34;
95% CI 3.04 to 3.68), but the negative LR fell (0.20; 95% CI 0.16 to 0.26). However,
ZKHQFULWHULDZHUHXVHGDJDLQWKHSRVLWLYH/5UHPDLQHGVLPLODU&,
2.80 to 4.18), while the negative LR increased to 0.71 (95% CI 0.66 to 0.77).
Sensitivity Analysis Excluding Individuals Reporting Lower GI Alarm
Symptoms from the Definition of IBS
When those with one or more lower GI alarm symptoms were excluded from
the definition of IBS, the specificities of all the different diagnostic criteria increased
to >90% in all cases, but this came at the expense of sensitivity which fell
dramatically (range 13.7% to 24.3%) (Table 5). As a result, positive LRs increased
slightly, but negative LRs increased dramatically, meaning that the absence of any of
the various diagnostic criteria performed poorly in ruling out IBS.
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DISCUSSION
This study has attempted to validate the Rome III criteria for IBS against an
accepted reference standard, and to compare their performance against all previous
symptom-based diagnostic criteria. It has demonstrated that the presence of the Rome
III criteria in a patient with lower GI symptoms increases the likelihood of having IBS
more than three-fold, whilst their absence reduces the likelihood of IBS by 60%.
These LRs mean that the Rome III criteria performed only modestly in predicting a
diagnosis of IBS, although the application of other existing symptom-based diagnostic
criteria yielded broadly similar LRs, with the exception of the negative LR for the
Rome I criteria, which was 0.06, meaning that the absence of the Rome I criteria
reduces the likelihood of a person having IBS by 94%. When the absence of lower GI
alarm symptoms was incorporated into the various diagnostic criteria in a sensitivity
analysis, their performance was even less optimal. Almost 50% of patients with IBS
met all four symptom-based diagnostic criteria, and one in four individuals met all
three iterations of the Rome criteria. Agreement between the various diagnostic
criteria was good to excellent in most cases.
Strengths of this study include the large sample size, with over 1800
individuals undergoing colonoscopy and providing complete symptom data, meaning
that this is one of the largest studies to validate available symptom-based diagnostic
criteria for IBS ever conducted. It is also, to our knowledge, the first study to validate
all existing diagnostic criteria for IBS simultaneously. We also performed sensitivity
analyses using the available diagnostic criteria for IBS. In addition, the study was
designed to adhere closely to the STARD guidelines for the reporting of studies of
diagnostic accuracy, with consecutive patients recruited, assessors blinded, and an
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accepted reference standard used. Finally, the fact that the majority of patients we
recruited were unselected referrals to secondary care means that the results are likely
to be generalizable to Gastroenterologists consulting with individuals with suspected
IBS in usual clinical practice.
Weaknesses of the study include the fact that we did not mandate colonoscopy
in all individuals with lower GI symptoms as part of the study design. This means that
in some individuals with IBS the diagnosis will have been made on clinical grounds
alone, and these individuals will not have been subject to colonoscopy. If the
diagnosis of IBS were correct in all these patients then the true positive rate of all the
symptom-based diagnostic criteria we assessed will have been artificially reduced,
leading to an underestimation of their accuracy. In addition, those who did undergo
colonoscopy and provide complete symptom data were not entirely representative of
the entire study population, with an over representation of White Caucasians, older
individuals, and patients with a higher BMI. However, in most cases the absolute
differences in demographic data between those undergoing colonoscopy and
providing complete symptom data and those who did not undergo colonoscopy were
modest. We did not perform longitudinal follow-up to ensure that an organic
diagnosis was not missed in individuals who met the reference standard for IBS,
although previous studies have suggested that a diagnosis of IBS is unlikely to be
revised during extended follow-up,
33
despite repeated investigation.
34
The reference
standard included symptom data from the questionnaire, which may have led to an
overestimation of the accuracy of the Rome III criteria. Finally, we did not attempt to
validate a new set of diagnostic criteria for IBS as part of this study, although this was
not the primary aim.
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As this study was conducted within usual clinical practice, and there is no
accepted gold-standard for the diagnosis of IBS, we did not mandate a minimum level
of blood work, such as complete blood count, C-reactive protein, or celiac serology,
in all individuals, nor did we make any recommendations as to whether upper GI or
small bowel investigations should be performed. Our study assumed that where initial
blood tests were abnormal, these would have prompted the responsible physician to
request further appropriate investigations to exclude organic disease. However, where
celiac serology was positive, distal duodenal biopsy was performed, and those
individuals with celiac disease were classified as having organic disease within our
analyses. The relevance of these issues is debatable, as a recent study suggests that,
within a North American population, there is no difference in the prevalence of celiac
disease in non-constipated IBS patients compared with controls,
35
and previous
studies that have applied a routine panel of blood tests or small bowel investigations
LQSDWLHQWVZLWKVXVSHFWHG,%6GHPRQVWUDWHD\LHOGIRURUJDQLFGLVHDVHRI13, 36, 37
In a previous meta-analysis of four validation studies of the Manning criteria
for IBS,
19, 27-29
containing a total of 574 patients, the positive and negative LRs of the
Manning criteria were 2.9 and 0.29 respectively.
26
The Manning criteria performed
best in the original validation study,
19
and when this study was excluded from the
analysis the positive and negative LRs fell to 2.7 and 0.33. The Rome I criteria, which
were validated in only one study containing 602 patients,
30
yielded a positive LR of
4.8 and a negative LR of 0.34.
26
Several of the studies included in this meta-analysis
classified subjects with diverticular disease, colorectal adenomas, or both, as having
organic disease. This may have led to the misclassification of individuals with true
IBS as having organic disease, a problem that does not apply to our study, as we were
careful to exclude these individuals from our organic lower GI disease category.
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A systematic review published in 2012 once again failed to identify any
studies validating the Rome III criteria.
38
More recently, a study from Denmark has
attempted to examine the accuracy of the Rome III criteria for IBS,
39
compared with
a reference standard of a primary care physician’s diagnosis of IBS. Among 499
patients with suspected IBS the Rome III criteria were fulfilled by 376, yielding a
sensitivity of 75%, similar to that we observed. However, as only patients with
suspected IBS were recruited, the specificity and likelihood ratios for the Rome III
criteria could not be estimated in this study.
The degree of agreement between the various diagnostic criteria was good to
very good in all instances. This is probably not unexpected, as the various criteria are
derived from each other, meaning that the same strengths and weaknesses are, for the
most part, passed on from one set of criteria to another. It was lowest for the Manning
and Rome III criteria. This is in keeping with a Greek study based in primary care,
40
and may reflect the number of revisions that the Rome III criteria have undergone.
Our observation that the Rome I and II criteria demonstrated high levels of agreement
is similar to that of Boyce et al. who reported that over 90% of individuals meeting
Rome I criteria also met Rome II criteria,
41
although other investigators have shown
that the level of agreement between the Rome I and Rome II criteria is lower.
42, 43
Previous studies have also suggested that agreement between the Rome I and
Manning criteria are poor,
41, 44
leading some to propose that the Rome criteria are too
restrictive.
41
Our findings show that, regardless of attempts to tighten the definition of IBS
by refining the symptoms used to diagnose the condition, there is little to choose
between the available diagnostic criteria. Despite a high prevalence of IBS in the
population under study, the positive predictive value of all these criteria was less than
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50%, suggesting that more accurate ways of detecting IBS are required if the
condition is to be diagnosed with any certainty, and the potential for unnecessary
investigation avoided. The Rome III criteria appeared to perform less well than
previous iterations, perhaps implying that they should be reappraised and brought
more in line with earlier definitions. In fact, a recent survey of internationally-
recognized experts reported that 80% of respondents felt that the Rome III criteria did
not reflect IBS adequately, in terms of the patients they saw in clinical practice, and
an identical proportion felt that a new international standardized set of criteria for the
diagnosis of IBS were required.
32
Even the exclusion of individuals reporting one or more lower GI alarm
symptoms from the various diagnostic criteria for IBS did not improve their
performance. This suggests that the presence of alarm symptoms in an individual does
not predict organic disease with any great accuracy, an issue we have identified in a
previous meta-analysis of observational studies.
45
Biomarkers may hold some
promise,
46, 47
although in the only fully published study to assess these they were no
more accurate than existing diagnostic criteria.
48
In the absence of an accurate and
accepted biomarker for the condition, and given that our sensitivity analyses using the
Rome III criteria did not improve their performance, it would seem that further
refinement of the symptoms that are used to define IBS is unlikely to prove fruitful.
The lack of a gold standard for the diagnosis of a clinical entity is not unique
to Gastroenterology and we need to use approaches that other disciplines, such as
Psychiatry, have used to overcome this problem. One possibility is to also evaluate
patients with colonoscopy and relevant biological markers, as well as obtain a detailed
symptom history.
47, 49, 50
The symptom data can then be compared with the biological
markers and colonoscopy results using statistical techniques, such as latent class
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analysis and Bayesian analysis.
51
These techniques can classify patients into
categories based on the underlying structure of the data, without relying on a gold
standard. Whilst these approaches have limitations, they are recognized as being a
significant methodological advance, and are recommended when there is no reference
standard.
52
Our data suggest the Gastroenterology research community should take
note and use new approaches to refine diagnostic criteria for IBS.
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Table 1. Kappa Statistic for Levels of Agreement Between the Rome and Manning Criteria for Irritable Bowel Syndrome.
Rome III criteria Rome II criteria Rome I criteria Manning criteria
FULWHULD
Rome III criteria 0.79 0.74 0.59
Rome II criteria 0.79 0.95 0.67
Rome I criteria 0.74 0.95 0.66
Manning criteria
FULWHULD
0.59 0.67 0.66
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Table 2. Demographics and Baseline Characteristics of Patients Undergoing
Colonoscopy and Providing Complete Rome III Symptom Data, Compared with
Those Who Did Not Undergo Colonoscopy.
Underwent colonoscopy
and provided complete
Rome III symptom data
(n = 1848)
Did not undergo
colonoscopy
(n = 2243)
P value*
Mean age (SD) 48.9 (17.1) 46.1 (18.1) <0.001
Mean body mass index
(SD)
27.3 (6.0) 26.7 (6.25) 0.009
Female gender (%) 1185 (64.1) 1366 (60.9) 0.03
Tobacco user (%) 375 (20.3) 442 (19.7) 0.76
Alcohol user (%) 1106 (59.8) 1250 (55.7) 0.02
Marital status (%)
Married or co-habiting
Divorced or separated
Never married
Widowed
1130 (61.1)
211 (11.4)
406 (22.0)
82 (4.4)
1280 (57.1)
249 (11.1)
568 (25.3)
102 (4.5)
0.04
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Educational level (%)
Elementary
High school
College or technical
school
University
Postgraduate
85 (4.6)
520 (28.1)
549 (29.7)
493 (26.7)
170 (9.2)
87 (3.9)
627 (28.0)
648 (28.9)
546 (24.3)
249 (11.1)
0.31
Ethnicity (%)
White Caucasian
South Asian
Middle-Eastern
First Nations
African
South-East Asian
Latin-American
1678 (90.8)
19 (1.0)
19 (1.0)
18 (1.0)
20 (1.1)
13 (0.7)
13 (0.7)
1917 (85.5)
41 (1.8)
38 (1.7)
18 (0.8)
31 (1.4)
35 (1.6)
22 (1.0)
0.004
Met Rome III criteria
for IBS (%)
555 (30.0) 579 (25.8) 0.19
*P value for independent samples tWHVWIRUFRQWLQXRXVGDWDDQG3HDUVRQȤ2 for
comparison of categorical data.
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Table 3. Prevalence of Organic Disease in Patients Meeting the Rome III Criteria
for IBS, Compared with Those Who Did Not.
Met Rome III
criteria for IBS
(n = 555)
Did not meet Rome III
criteria for IBS
(n = 1293)
P
value*
Crohn’s disease (%) 48 (8.6) 84 (6.5) 0.11
Ulcerative colitis (%) 34 (6.1) 59 (4.6) 0.16
Indeterminate colitis (%) 24 (4.3) 42 (3.2) 0.27
Colorectal cancer (%) 13 (2.3) 28 (2.2) 0.86
Lymphocytic colitis (%) 8 (1.4) 15 (1.2) 0.65
Celiac disease (%) 8 (1.4) 13 (1.0) 0.47
Radiation enteritis (%) 8 (1.4) 9 (0.7) 0.18
Collagenous colitis (%) 4 (0.7) 4 (0.3) 0.25
Non-specific GI
ulceration (%)
3 (0.5) 2 (0.2) 0.16
*P value for Fisher’s exact test for comparison of categorical data.
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Table 4. Sensitivity, Specificity, Positive and Negative Predictive Values, and Positive and Negative Likelihood Ratios for the Rome and
Manning Criteria for Irritable Bowel Syndrome.
Sensitivity
(95% CI)
Specificity
(95% CI )
Positive
predictive value
(95% CI)
Negative
predictive value
(95% CI)
Positive
likelihood ratio
(95% CI)
Negative
likelihood ratio
(95% CI)
Rome III criteria 68.8%
(63.8% – 73.3%)
79.5%
(77.4% – 81.5%)
45.2%
(41.1% – 49.4%)
91.2%
(89.5% – 92.6%)
3.35
(2.97 – 3.79)
0.39
(0.34 – 0.46)
Rome II criteria 90.2%
(86.8% – 92.8%)
71.7%
(69.4% – 74.0%)
44.8%
(41.3% – 48.4%)
96.6%
(95.4% – 97.6%)
3.19
(2.92 – 3.48)
0.14
(0.10 – 0.19)
Rome I criteria 95.8%
(93.2% – 97.4%)
70.6%
(68.2% – 72.8%)
45.2%
(41.8% – 48.7%)
98.5%
(97.6% – 99.1%)
3.26
(3.00 – 3.53)
0.06
(0.04 – 0.10)
Manning criteria
FULWHULD
85.0%
(81.0% – 88.2%)
74.6%
(72.3% – 76.7%)
45.8%
(42.2% – 49.5%)
95.1%
(93.8% – 96.2%)
3.34
(3.04 – 3.68)
0.20
(0.16 – 0.26)
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Manning criteria
FULWHULD
61.9%
(56.8% – 66.7%)
81.8%
(79.7% – 83.7%)
45.6%
(41.3% – 50.0%)
89.7%
(88.0% – 91.2%)
3.39
(2.97 – 3.88)
0.47
(0.41 – 0.53)
Manning criteria
FULWHULD
36.1%
(31.3% – 41.1%)
89.5%
(87.8% – 90.9%)
45.4%
(39.7% – 51.1%)
85.2%
(83.4% – 86.9%)
3.42
(2.80 – 4.18)
0.71
(0.66 – 0.77)
Rome III criteria
with abdominal
pain or
discomfort
replaced by
bloating
54.3%
(49.2% – 59.4%)
76.4%
(74.2% – 78.5%)
36.9%
(32.9% – 41.0%)
86.8%
(84.9% – 88.6%)
2.31
(2.02 – 2.63)
0.60
(0.53 – 0.67)
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Rome III criteria
with abdominal
pain or
discomfort and
bloating
53.1%
(47.9% – 58.3%)
85.1%
(83.2% – 86.9%)
46.7%
(41.8% – 51.6%)
88.1%
(86.4% – 89.8%)
3.58
(3.06 – 4.17)
0.55
(0.49 – 0.61)
Rome III criteria
with daily
abdominal pain
or discomfort
29.0%
(24.7% – 33.7%)
92.0%
(90.5% – 93.2%)
48.1%
(41.7% – 54.5%)
83.5%
(81.6% – 85.2%)
3.61
(2.87 – 4.55)
0.77
(0.72 – 0.82)
Rome III criteria
with irregular
bowel habit
34.4%
(29.8% – 39.3%)
91.1%
(89.6% – 92.5%)
49.1%
(43.1% – 55.1%)
84.9%
(83.0% – 86.5%)
3.88
(3.14 – 4.81)
0.72
(0.67 – 0.78)
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Table 5. Sensitivity, Specificity, Positive and Negative Predictive Values, and Positive and Negative Likelihood Ratios for the Rome and
Manning Criteria for Irritable Bowel Syndrome, Excluding Individuals Reporting Lower GI Alarm Symptoms from the Definition of
IBS.
Sensitivity
(95% CI)
Specificity
(95% CI )
Positive
predictive value
(95% CI)
Negative
predictive value
(95% CI)
Positive
likelihood ratio
(95% CI)
Negative
likelihood ratio
(95% CI)
Rome III criteria 17.4%
(13.9% – 21.5%)
95.6%
(94.4% – 96.5%)
49.6%
(42.0% – 58.7%)
82.1%
(80.0% – 83.6%)
3.92
(2.85 – 5.38)
0.86
(0.83 – 0.91)
Rome II criteria 23.3%
(19.4% – 27.8%)
94.5%
(93.2% – 95.5%)
51.7%
(44.9% – 59.5%)
82.9%
(80.8% – 84.4%)
4.21
(3.20 – 5.53)
0.81
(0.77 – 0.86)
Rome I criteria 24.3%
(20.3% – 28.8%)
93.9%
(92.6% – 95.0%)
50.5%
(44.0% – 58.1%)
83.0%
(80.9% – 84.4%)
4.01
(3.08 – 5.22)
0.81
(0.76 – 0.85)
Manning criteria
FULWHULD
13.7%
(10.6% – 17.6%)
97.1%
(96.1% – 97.8%)
54.1%
(45.3% – 64.6%)
81.6%
(79.6% – 83.1%)
4.66
(3.18 – 6.82)
0.89
(0.85 – 0.93)
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FIGURE LEGENDS
Figure 1. Flow of Study Participants.
Figure 2. Overlap Between Diagnostic Criteria for Irritable Bowel Syndrome.
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4224 consecutive
patients enrolled
1981 patients
underwent
complete
colonoscopy
2243 patients did
not undergo
colonoscopy
1848 patients
provided complete
Rome III symptom
and colonoscopy
data
133 patients did
not provide
complete
symptom or
colonoscopy data
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